TD Cowen Cuts Astera Labs (NASDAQ:ALAB) Price Target to $170.00

Astera Labs (NASDAQ:ALAB) had its price objective decreased by research analysts at TD Cowen from $225.00 to $170.00 in a research note issued to investors on Wednesday. The firm currently has a “hold” rating on the stock. TD Cowen’s price objective suggests a potential downside of 5.19% from the stock’s previous close.

Several other analysts also recently issued reports on ALAB. Morgan Stanley lifted their price target on shares of Astera Labs from $155.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, August 29th. Deutsche Bank Aktiengesellschaft raised their price objective on Astera Labs from $160.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Zacks Research cut Astera Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Evercore ISI raised their price objective on Astera Labs from $104.00 to $215.00 and gave the company an “outperform” rating in a research note on Wednesday, August 6th. Finally, Bank of America assumed coverage on Astera Labs in a research note on Friday, October 3rd. They set a “neutral” rating and a $230.00 price objective on the stock. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $167.00.

Astera Labs Trading Down 6.4%

NASDAQ ALAB opened at $179.31 on Wednesday. The company has a fifty day simple moving average of $196.79 and a 200 day simple moving average of $138.70. Astera Labs has a 12-month low of $47.13 and a 12-month high of $262.90. The company has a market cap of $29.80 billion, a P/E ratio of 320.20, a PEG ratio of 4.70 and a beta of 1.37.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.10. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business had revenue of $230.58 million during the quarter, compared to the consensus estimate of $206.42 million. During the same quarter last year, the firm posted $0.23 EPS. Astera Labs’s revenue was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Sell-side analysts predict that Astera Labs will post 0.34 EPS for the current year.

Insider Activity

In other Astera Labs news, COO Sanjay Gajendra sold 280,000 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $170.02, for a total transaction of $47,605,600.00. Following the completion of the transaction, the chief operating officer owned 5,525,545 shares in the company, valued at $939,453,160.90. This trade represents a 4.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Manuel Alba sold 183,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $173.27, for a total value of $31,708,410.00. Following the sale, the director owned 385,863 shares in the company, valued at approximately $66,858,482.01. This represents a 32.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 1,092,997 shares of company stock valued at $192,231,120. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Astera Labs

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Astera Labs in the second quarter worth approximately $29,000. Bernard Wealth Management Corp. bought a new position in Astera Labs during the second quarter valued at approximately $36,000. Clearstead Trust LLC grew its position in Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after acquiring an additional 461 shares during the last quarter. Advisors Asset Management Inc. grew its position in Astera Labs by 68.6% during the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after acquiring an additional 194 shares during the last quarter. Finally, Manchester Capital Management LLC grew its position in Astera Labs by 141.5% during the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after acquiring an additional 283 shares during the last quarter. 60.47% of the stock is currently owned by institutional investors.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.